专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014011853A3 IGY FROM NOROVIRUS P PARTICLES AND THEIR DERIVATIVES 审中-公开
标题翻译：来自NOROVIRUS P颗粒及其衍生物的IGY
公开(公告)号：WO2014011853A3
公开(公告)日：2014-03-06
申请号：PCT/US2013050044
申请日：2013-07-11
申请人： CHILDRENS HOSP MEDICAL CENTER , DAI YING-CHUN
发明人： DAI YING-CHUN , JIANG XI
IPC分类号： C07K16/08 , A61K39/42 , C12P21/08
CPC分类号： C07K16/02 , A61K2039/505 , C07K16/10
摘要： A method for large-scale production of anti-NoV antibodies for use as a potential treatment for NoV disease using passive immunization. NoV-specific immunoglobulins (IgY) can be produced by immunizing chickens with NoV P particles. The birds continuously produced high titers of antibodies in their eggs for at least 3 months, in which NoV-specific antibody levels reached 4.7-9.2 mg/egg yolk. The egg yolk antibodies strongly reacted with NoV P particles by both ELISA and Western blot and blocked NoV virus-like particle (VLP) and P particle binding to the histo-blood group antigen (HBGA) receptors with a BT50 of about 1 :800. The chicken IgY remain stable at 70°C for 30 min or treatment at pH 4 to 9 for 3 hr, demonstrating that chicken IgY provides large-scale production of anti-NoV antibodies for use in passive immunization against NoV infection.
摘要翻译：用于大规模生产抗NoV抗体的方法，用作使用被动免疫的NoV疾病的潜在治疗。通过用NoV P颗粒免疫鸡可以产生NoV特异性免疫球蛋白（IgY）。鸟类在其卵中连续产生高滴度抗体至少3个月，其中NoV特异性抗体水平达到4.7-9.2mg /蛋黄。蛋黄抗体通过ELISA和Western印迹与NoV病毒样颗粒（VLP）和P颗粒结合到具有约1:800的BT50的组织 - 血型抗原（HBGA）受体而与NoV P颗粒强烈反应。鸡IgY在70℃保持30分钟或在pH4至9下处理3小时，表明鸡IgY提供大规模生产抗NoV抗体用于针对NoV感染的被动免疫。

2. 发明申请

WO2012159052A2 TARGETED DELIVERY OF PROTEINS ACROSS THE BLOOD BRAIN BARRIER 审中-公开
标题翻译：通过血液脑屏障定向递送蛋白质
公开(公告)号：WO2012159052A2
公开(公告)日：2012-11-22
申请号：PCT/US2012038627
申请日：2012-05-18
申请人： CHILDRENS HOSP MEDICAL CENTER , PAN DAO
发明人： PAN DAO
CPC分类号： C07K14/47 , A61K9/0019 , A61K38/47 , A61K48/0075 , C07K2319/10 , C07K2319/33 , C12N2740/15043 , C12Y302/01076
摘要： Embodiments of the invention are directed to compositions comprising a peptide sequence, or a nucleic acid encoding the same, wherein the peptide sequence includes a receptor-binding region of apolipoprotein E (apoE), or a sequence variant or fragment thereof, for directing delivery of a given protein or therapeutic across the blood brain barrier. Embodiments of the invention are also directed to methods of using the compositions for treating or preventing a neurological disorder, disease, or symptom in a subject in need thereof.
摘要翻译：本发明的实施方案涉及包含肽序列或其编码的核酸的组合物，其中所述肽序列包括载脂蛋白E（apoE）的受体结合区或其序列变体或片段，用于指导递送给予的蛋白质或治疗性血脑屏障。本发明的实施方案还涉及使用组合物治疗或预防有需要的受试者的神经障碍，疾病或症状的方法。

3. 发明申请

WO2011140441A3 METHODS AND SYSTEMS FOR CONVERTING PRECURSOR CELLS INTO INTESTINAL TISSUES THROUGH DIRECTED DIFFERENTIATION 审中-公开
标题翻译：通过指导性差异将前列腺细胞转化为细胞组织的方法和系统
公开(公告)号：WO2011140441A3
公开(公告)日：2012-04-05
申请号：PCT/US2011035518
申请日：2011-05-06
申请人： CHILDRENS HOSP MEDICAL CENTER , WELLS JAMES M , ZORN AARON M , SPENCE JASON R , SHROYER NOAH F
发明人： WELLS JAMES M , ZORN AARON M , SPENCE JASON R , SHROYER NOAH F
IPC分类号： C12N5/071 , C07K14/47 , C07K14/50 , C12N5/02
CPC分类号： C12N5/0679 , C12N5/0661 , C12N2501/119 , C12N2501/155 , C12N2501/16 , C12N2501/385 , C12N2501/415 , C12N2502/02 , C12N2502/45
摘要： The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal "organoids" were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.
摘要翻译：来自人胚胎和多能干细胞（PSCs）的复杂器官组织的产生仍然是翻译研究的主要挑战。显示PSC可以通过以逐步方式调节多种信号传导途径的组合活性而被引导以在体外分化成肠组织，有效地重现体内胎儿肠发育。所得到的肠“有机体”是由包含平滑肌层的间质包围的极化柱状上皮组成的三维结构。将上皮图案化为具有肠的所有主要功能性细胞类型的隐窝样SOX9阳性增殖区和绒毛状结构。培养系统用于证明在肠内分泌异常症中突变的前内分泌转录因子的NEUROG3的表达足以促进对肠内分泌细胞谱系的分化。总之，PSC衍生的人肠组织应该允许对人肠发育，体内平衡和疾病进行前所未有的研究。

4. 发明申请

WO2010094009A3 METHODS AND COMPOSITIONS FOR THE TREATMENT OF RAS ASSOCIATED DISORDERS 审中-公开
标题翻译：治疗RAS相关疾病的方法和组合
公开(公告)号：WO2010094009A3
公开(公告)日：2010-10-07
申请号：PCT/US2010024237
申请日：2010-02-15
申请人： CHILDRENS HOSP MEDICAL CENTER , RATNER NANCY , SANCHEZ YOLANDA , JOHANSSON GUNNAR , SEIBEL WILLIAM
发明人： RATNER NANCY , SANCHEZ YOLANDA , JOHANSSON GUNNAR , SEIBEL WILLIAM
IPC分类号： A61K31/382 , A61K31/4015 , A61K31/415 , A61K31/435 , A61P35/00
CPC分类号： A61K31/382 , A61K31/4015 , A61K31/415 , A61K31/435
摘要： The instant disclosure relates to compositions that may be useful as therapeutic agents for the treatment of disorders associated or caused by Ras deregulation or dysregulation, for example, disorders associated with alterations in the NFl gene such as neurofibromatosis type I and/or fungal infections such as those caused by Candida albicans.
摘要翻译：本公开涉及可用作治疗与Ras失调或调节紊乱相关或引起的疾病的治疗剂的组合物，例如与NF1基因改变相关的病症，例如I型神经纤维瘤病和/或真菌感染，例如那些由白色念珠菌引起的。

5. 发明申请

WO2007047458A3 DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL 审中-公开
标题翻译：用NGAL诊断和监测慢性肾脏疾病
公开(公告)号：WO2007047458A3
公开(公告)日：2009-04-23
申请号：PCT/US2006040132
申请日：2006-10-13
申请人： CHILDRENS HOSP MEDICAL CENTER , UNIV COLUMBIA , BARASCH JONATHAN M , DEVARAJAN PRASAD , NICKOLAS THOMAS L , MORI KIYOSHI
发明人： BARASCH JONATHAN M , DEVARAJAN PRASAD , NICKOLAS THOMAS L , MORI KIYOSHI
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N2800/347 , G01N2800/52
摘要： A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
摘要翻译：通过检测尿液，血清或血浆中嗜中性粒细胞明胶酶相关脂质运载蛋白（NGAL）的量，评估患有或有发生慢性肾损伤或疾病风险（包括慢性肾衰竭（CRF））的哺乳动物的进行性肾脏状态的方法在不连续的时间段以及随着时间推移的样本。慢性肾功能衰竭患者长时间NGAL水平增加可以诊断肾脏疾病恶化。 NGAL的这种升高与慢性肾脏疾病或CRF恶化的其他指标有关，例如血清肌酐升高，尿蛋白分泌增加以及肾小球滤过率（GFR）下降。通过患者治疗前和治疗后NGAL水平证实，适当检测恶化（或改善，如果已经开始治疗）随时间变化的肾状态可帮助临床医师设计和/或维持适当的治疗方案以减缓或停止CRF的进展。

6. 发明申请

WO2008143890A3 BIOMARKERS FOR SEPTIC SHOCK PATIENTS 审中-公开
标题翻译：生物标志物对于休克患者
公开(公告)号：WO2008143890A3
公开(公告)日：2009-03-12
申请号：PCT/US2008006172
申请日：2008-05-14
申请人： CHILDRENS HOSP MEDICAL CENTER , WONG HECTOR R
发明人： WONG HECTOR R
IPC分类号： G01N33/68
CPC分类号： G01N33/6869 , G01N2333/5421 , G01N2800/26
摘要： The instant invention relates generally to the use of IL-8 as a biomarker in septic shock patients as an indicator of the likelihood of survival. The instant invention further relates to the use of IL-8 as a biomarker in septic shock patients for the selection of appropriate therapies. The instant invention further relates to the use of IL-8 as a biomarker for the purposes of structuring, conducting, or evaluating clinical trials or data from clinical trials.
摘要翻译：本发明一般涉及在脓毒性休克患者中作为生物标志物的IL-8作为生存可能性的指标的用途。本发明还涉及IL-8作为脓毒性休克患者中的生物标志物用于选择适当疗法的用途。本发明还涉及IL-8作为生物标志物用于结构化，进行或评价临床试验或临床试验数据的用途。

7. 发明申请

WO2007130486A3 CANNULA WITH REMOVABLE SLEEVE 审中-公开
标题翻译：带可拆卸套管的肛门
公开(公告)号：WO2007130486A3
公开(公告)日：2008-12-04
申请号：PCT/US2007010683
申请日：2007-05-03
申请人： CHILDRENS HOSP MEDICAL CENTER , EGHTESADY PIROOZ
发明人： EGHTESADY PIROOZ
IPC分类号： A61M5/00 , A61M31/00
CPC分类号： A61M25/0041 , A61M25/007 , A61M25/0662 , A61M2025/0681
摘要： A venous cannula is disclosed having an insertion hole near the distal end and a leading end hole at the distal end. The cannula further includes a removable sleeve that is fitted within the insertion hole and preferably extends at least from the insertion hole to the leading end hole. In a preferred embodiment, the cannula also includes an introducer that fits within the removable sleeve and extends at least the length of the removable sleeve. The removable sleeve and introducer are designed to facilitate use of the Seldinger technique with the venous cannula. Additionally, a method for use of the Seldinger technique with the cannula is disclosed.
摘要翻译：公开了一种静脉插管，其具有在远端附近的插入孔和在远端的前端孔。插管还包括可拆卸的套筒，该套筒装配在插入孔内，并且优选地至少从插入孔延伸到前端孔。在优选实施例中，套管还包括导引器，其适配在可移除套筒内并至少延伸至可移除套筒的长度。可拆卸的套筒和导引器设计成便于使用Seldinger技术与静脉插管。另外，公开了使用Seldinger技术与插管的方法。

8. 发明申请

WO2007064675A2 OPTIMIZATION AND INDIVIDUALIZATION OF MEDICATION SELECTION AND DOSING 审中-公开
标题翻译：药物选择和剂量的优化和个体化
公开(公告)号：WO2007064675A2
公开(公告)日：2007-06-07
申请号：PCT/US2006045631
申请日：2006-11-28
申请人： CHILDRENS HOSP MEDICAL CENTER , GLAUSER TRACY A , WENSTRUP RICHARD J , VINKS ALEXANDER A , PESTIAN JOHN
发明人： GLAUSER TRACY A , WENSTRUP RICHARD J , VINKS ALEXANDER A , PESTIAN JOHN
IPC分类号： G06F19/00
CPC分类号： G06F19/3437 , C12Q1/6883 , C12Q2600/106 , G01N33/94 , G06F19/24 , G06F19/326 , G06F19/3456 , G06Q50/24 , G16H50/50
摘要： The invention provides population models, methods, and algorithms for targeting a dosing regimen or compound selection to an individual patient. The methods and algorithms of the invention utilize population models that incorporate genotype information for genes encoding drug metabolizing enzymes for one or more compounds of interest. The methods allow integration of genotype information for one or more genes encoding a drug metabolizing enzyme, particularly a cytochrome P450 gene with patient data. The methods allow integration of genotype information and the effect of one or more compounds on one or more drug metabolizing enzymes. The methods allow iterative feedback of drug metabolizing data obtained from a patient into the process of generating a dosage regimen recommendation for a compound of interest for an individual patient.
摘要翻译：本发明提供用于将给药方案或化合物选择靶向个体患者的种群模型，方法和算法。本发明的方法和算法利用对于一种或多种感兴趣的化合物编码药物代谢酶的基因的基因型信息的群体模型。该方法允许将编码药物代谢酶，特别是细胞色素P450基因的一种或多种基因的基因型信息与患者数据整合。该方法允许基因型信息的整合和一种或多种化合物对一种或多种药物代谢酶的影响。所述方法允许从患者获得的药物代谢数据的迭代反馈到针对个体患者感兴趣的化合物产生剂量方案推荐的过程。

9. 发明申请

WO2007030375A2 LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES 审中-公开
标题翻译：用于NAFLD和相关疾病的LYSOSOMAL ACID LIPASE THERAPY
公开(公告)号：WO2007030375A2
公开(公告)日：2007-03-15
申请号：PCT/US2006034044
申请日：2006-08-31
申请人： CHILDRENS HOSP MEDICAL CENTER , GRABOWSKI GREGORY A
发明人： GRABOWSKI GREGORY A
CPC分类号： A61K38/465 , A61K9/0019 , A61K45/06 , A61K48/00 , C12Y301/01013 , A61K2300/00
摘要： The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome,
摘要翻译：本发明包括通过使用溶酶体酸的药物制剂来治疗或缓解NAFLD（非酒精性脂肪性肝病）和与NAFLD相关的病症的方法和组合物，包括脂肪肝疾病，非酒精性脂肪性肝炎（NASH）和肝硬化脂肪酶或相关蛋白质和/或多肽。本发明还涉及用于治疗代谢综合征的联合治疗治疗。作为用于治疗代谢综合征的联合治疗方案的一部分，溶酶体酸性脂肪酶或相关蛋白质和/或多肽的药物制剂被用作治疗NAFLD（和NASH）的组合治疗方案的一部分，其包括构成代谢综合征的病症，

10. 发明申请

WO2006083390A3 EOTAXIN-3 IN EOSINOPHILIC ESOPHAGITIS 审中-公开
标题翻译： EOTAXIN-3在嗜酸性食管炎中的应用
公开(公告)号：WO2006083390A3
公开(公告)日：2006-12-07
申请号：PCT/US2005044456
申请日：2005-12-07
申请人： CHILDRENS HOSP MEDICAL CENTER , ROTHENBERG MARC ELLIOT
发明人： ROTHENBERG MARC ELLIOT
IPC分类号： G01N33/68 , A61K38/19
CPC分类号： C12Q1/6883 , A61K31/56 , C12Q2600/158 , C12Q2600/16 , G01N33/6893 , G01N2800/06 , G01N2800/24
摘要： Eotaxin-3, as a marker for eosinophilic esophagitis and methods of assessing, mitigating, and monitoring eosinophilic esophagitis by altering eotaxin-3 and/or CCR3 function, are disclosed.
摘要翻译： Eotaxin-3作为嗜酸细胞性食管炎的标记，以及通过改变eotaxin-3和/或CCR3功能来评估，减轻和监测嗜酸性粒细胞性食管炎的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式